Relay Therapeutics Inc (RLAY)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Relay Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 17 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 18.80 $ — 89% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 38.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 13
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.53 | -1.68 – -1.39 | 12 | 5.2% | 10 |
| 12/31/2027 | -1.64 | -1.87 – -1.27 | 15 | -7.5% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.41 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.45 | – | 0 | – | – | -58 | -58 |
| 2025: Q1 | -0.46 | – | 8 | -23.30 | -1,003.60 | -73 | -74 |
| 2025: Q2 | -0.41 | – | 1 | – | -10,395.10 | -55 | -55 |
| 2025: Q3 | -0.43 | – | 0 | – | – | -62 | -62 |
| 2025: Q4 | -0.32 | – | 7 | – | -784.10 | -45 | -45 |
| 2026: Q1 | -0.41 | – | 3 | -60.90 | -2,443.00 | -51 | -51 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 0 | -50 | -49 | -19.63 | -44 | -111 | 429 |
| 2019 | 0 | -84 | -67 | -15.53 | -66 | -180 | 393 |
| 2020 | 83 | -56 | -52 | -0.58 | -102 | 763 | 800 |
| 2021 | 3 | -365 | -364 | -3.82 | -74 | 898 | 1,008 |
| 2022 | 1 | -299 | -291 | -2.59 | -229 | 950 | 1,100 |
| 2023 | 26 | -373 | -342 | -2.79 | -300 | 752 | 844 |
| 2024 | 10 | -372 | -338 | -2.36 | -249 | 778 | 871 |
| 2025 | 15 | -303 | -276 | -1.61 | -235 | 567 | 621 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Relay Therapeutics, Inc. ist als Präzisionsmedizin-Unternehmen im klinischen Stadium tätig.
| Employees | 193 |
|---|---|
| Headquarters | Cambridge, MA |
| Address | 60 Hampshire Street, 02139 Cambridge, United States |
| Phone | 617 370 8837 |
| Website | relaytx.com |
| IPO Date | 16. Jul 2020 |
| ISIN | US75943R1023 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | CEO, President & Director | 1974 |
| Mark Murcko Ph.D. | Founder & Independent Director | 1960 |
| Thomas Catinazzo | Chief Financial Officer | 1977 |
| Peter Rahmer | Chief Corporate Development Officer | 1982 |
| Donald A. Bergstrom M.D., Ph.D. | President of Research & Development | 1972 |
| Dorothee Kern Ph.D. | Founder | – |
| David Elliot Shaw Ph.D. | Founder | 1951 |
| Matthew P. Jacobson Ph.D. | Founder | – |
| Jim Watters Ph.D. | Chief Scientific Officer | – |
| Soo-Yeun Lim J.D. | Senior VP & General Counsel | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 28. Jul 2026 | Catinazzo Thomas | Chief Financial Officer | Sell | 1,459 | 18.61 | 27,152 |
| 28. Jul 2026 | Rahmer Peter | See remarks | Sell | 748 | 18.61 | 13,920 |
| 28. Jul 2026 | Bergstrom Donald A | President, R&D | Sell | 2,237 | 18.61 | 41,631 |
| 7. Jul 2026 | Patel Sanjiv | President and CEO | Sell | 48,199 | 19.58 | 943,736 |
| 6. Jul 2026 | Bergstrom Donald A | President, R&D | Sell | 8,660 | 18.71 | 162,029 |
| 6. Jul 2026 | Catinazzo Thomas | Chief Financial Officer | Sell | 17,717 | 18.69 | 331,131 |
| 30. Jun 2026 | Patel Sanjiv | President and CEO | Other | 3,056 | 6.95 | 21,239 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.